PURPOSE: Cytokines play a pivotal role in Hodgkin's lymphoma (HL). Because interleukin-6 (IL-6) induces expression of hepcidin, one of the principal regulators of iron metabolism, we studied the contribution of hepcidin in anemia in HL at diagnosis. PATIENTS AND METHODS: Plasma samples from 65 patients with HL were analyzed for hepcidin levels using a combination of weak cation exchange chromatography and time-of-flight mass spectrometry; cytokine levels were analyzed using enzyme-linked immunosorbent assays and parameters of iron metabolism and acute-phase reaction. RESULTS: Hepcidin plasma levels were significantly higher in HL patients when compared with controls, independent of the presence of anemia (P = .001). In the subset of patients with anemia, hepcidin levels inversely correlated with hemoglobin levels (P = .01). Analyzing parameters of iron metabolism, hepcidin levels showed a positive correlation with ferritin (P < .001) and an inverse correlation to iron and iron-binding capacity. Hepcidin strongly correlated to IL-6 levels (P < .001) but not to IL-10 or thymus and activation-regulated cytokine (TARC)/chemokine (C-C motif) ligand 17 (CCL17) levels. In a multivariate regression analysis, IL-6 and fibrinogen levels were independently associated with hepcidin. Higher hepcidin levels were observed in patients with more aggressive disease characteristics: stage IV disease (P = .01), presence of B symptoms (P = .03), and International Prognostic Score > 2 (P = .005). CONCLUSION: Our findings suggest that in HL, hepcidin is upregulated by IL-6. Elevated hepcidin levels result in iron restriction and signs of anemia of chronic inflammation, although hepcidin-independent mechanisms contribute to development of anemia in HL.
PURPOSE: Cytokines play a pivotal role in Hodgkin's lymphoma (HL). Because interleukin-6 (IL-6) induces expression of hepcidin, one of the principal regulators of iron metabolism, we studied the contribution of hepcidin in anemia in HL at diagnosis. PATIENTS AND METHODS: Plasma samples from 65 patients with HL were analyzed for hepcidin levels using a combination of weak cation exchange chromatography and time-of-flight mass spectrometry; cytokine levels were analyzed using enzyme-linked immunosorbent assays and parameters of iron metabolism and acute-phase reaction. RESULTS:Hepcidin plasma levels were significantly higher in HL patients when compared with controls, independent of the presence of anemia (P = .001). In the subset of patients with anemia, hepcidin levels inversely correlated with hemoglobin levels (P = .01). Analyzing parameters of iron metabolism, hepcidin levels showed a positive correlation with ferritin (P < .001) and an inverse correlation to iron and iron-binding capacity. Hepcidin strongly correlated to IL-6 levels (P < .001) but not to IL-10 or thymus and activation-regulated cytokine (TARC)/chemokine (C-C motif) ligand 17 (CCL17) levels. In a multivariate regression analysis, IL-6 and fibrinogen levels were independently associated with hepcidin. Higher hepcidin levels were observed in patients with more aggressive disease characteristics: stage IV disease (P = .01), presence of B symptoms (P = .03), and International Prognostic Score > 2 (P = .005). CONCLUSION: Our findings suggest that in HL, hepcidin is upregulated by IL-6. Elevated hepcidin levels result in iron restriction and signs of anemia of chronic inflammation, although hepcidin-independent mechanisms contribute to development of anemia in HL.
Authors: David B Chou; Brian Sworder; Nicolas Bouladoux; Cindy N Roy; Amiko M Uchida; Michael Grigg; Pamela G Robey; Yasmine Belkaid Journal: J Leukoc Biol Date: 2012-04-09 Impact factor: 4.962
Authors: E J deAndrés-Galiana; J L Fernández-Martínez; O Luaces; J J Del Coz; R Fernández; J Solano; E A Nogués; Y Zanabilli; J M Alonso; A R Payer; J M Vicente; J Medina; F Taboada; M Vargas; C Alarcón; M Morán; A González-Ordóñez; M A Palicio; S Ortiz; C Chamorro; S Gonzalez; A P González-Rodríguez Journal: Clin Transl Oncol Date: 2015-04-21 Impact factor: 3.405
Authors: Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Luciana Tanca; Maria Cristina Cherchi; Carlo Floris; Itaru Omoto; Antonio Barracca; Tomas Ganz Journal: Haematologica Date: 2014-09-19 Impact factor: 9.941
Authors: Anne-Marie Charpentier; Debra L Friedman; Suzanne Wolden; Cindy Schwartz; Bethany Gill; Jenna Sykes; Alisha Albert-Green; Kara M Kelly; Louis S Constine; David C Hodgson Journal: Int J Radiat Oncol Biol Phys Date: 2016-12-01 Impact factor: 7.038